MMP9 and prostate carcinoma: Accordingly, increased IFN-β expression in prostate cancer cells was found to downregulate osteoclast activation genes like receptor activator of NF-κB (RANK) and matrix metalloproteinase-9 (MMP9) in RAW264.7 precursor cells co-cultured with tumor cells (88).